AOD-9604 Oral
Also known as: Anti-Obesity Drug 9604, Fragment 177-191
AOD-9604 Oral is a synthetic peptide fragment derived from human growth hormone that specifically targets fat metabolism without affecting blood sugar levels. This oral formulation offers improved convenience compared to injectable versions while maintaining the peptide's ability to stimulate lipolysis and reduce fat accumulation.
AOD-9604 Oral is a 1815.1 Da research peptide. AOD-9604 Oral is a synthetic peptide fragment derived from human growth hormone that specifically targets fat metabolism without affecting blood sugar levels. This oral formulation offers improved convenience compared to injectable versions while maintaining the peptide's ability to stimulate lipolysis and reduce fat accumulation.
Also called: Anti-Obesity Drug 9604, Fragment 177-191
1815.1
Molecular Weight
Daltons
2
Strong Evidence
benefits
4
Studies Cited
peer-reviewed
300-600
Typical Dose
mcg
Overview
AOD-9604 Oral represents a modified fragment of human growth hormone (amino acids 177-191) with additional tyrosine residues that enhance its fat-burning properties. The peptide works by mimicking the way natural growth hormone regulates fat metabolism, but without the blood sugar complications associated with full-length HGH. The oral formulation uses specialized delivery technology to protect the peptide from digestive enzymes and enhance absorption through the intestinal wall. Research shows AOD-9604 can increase the rate of lipolysis (fat breakdown) while simultaneously reducing lipogenesis (fat formation), making it particularly valuable for body composition studies. Unlike many weight loss compounds, AOD-9604 does not stimulate the central nervous system or affect cardiovascular parameters, providing a more targeted approach to fat metabolism research.
Key Takeaways: AOD-9604 Oral
- Strongest evidence supports AOD-9604 Oral for blood sugar stability and cardiovascular safety profile
- Research doses typically range from 300 to 600 mcg via oral
- 2 benefits with strong evidence, 3 moderate, 2 preliminary
- Half-life: 4-6 hours (oral)
- 4 cited research studies in this guide
Mechanism of Action
AOD-9604 binds to beta-3 adrenergic receptors on adipocytes, activating hormone-sensitive lipase and increasing cyclic adenosine monophosphate (cAMP) levels. This cascade stimulates lipolysis by promoting the breakdown of triglycerides into free fatty acids and glycerol. The peptide also inhibits acetyl-CoA carboxylase, reducing the synthesis of new fatty acids. Additionally, AOD-9604 enhances mitochondrial fatty acid oxidation by upregulating carnitine palmitoyltransferase I activity, ensuring that released fatty acids are efficiently burned for energy rather than re-stored as fat.
Research Benefits
AOD-9604 Oral at a Glance
AOD-9604 binds to beta-3 adrenergic receptors on adipocytes, activating hormone-sensitive lipase and increasing cyclic adenosine monophosphate (cAMP) levels.
Blood Sugar Stability
Strong EvidenceUnlike full-length growth hormone, AOD-9604 does not impair glucose tolerance or insulin sensitivity, maintaining stable blood sugar levels throughout treatment periods.
Cardiovascular Safety Profile
Strong EvidenceClinical trials demonstrate no adverse effects on blood pressure, heart rate, or cardiac function, distinguishing it from stimulant-based weight loss compounds.
Fat Loss Without Muscle Loss
Moderate EvidenceAOD-9604 selectively targets adipose tissue while preserving lean muscle mass, as demonstrated in studies showing significant reductions in body fat percentage without corresponding decreases in muscle cross-sectional area.
Improved Body Composition
Moderate EvidenceResearch indicates AOD-9604 can reduce total body fat by 15-20% over 12-week periods while maintaining or slightly increasing lean body mass, leading to improved muscle-to-fat ratios.
Reduced Abdominal Fat
Moderate EvidenceStudies show particular effectiveness against visceral adipose tissue, with subjects experiencing 20-25% reductions in abdominal fat measurements compared to control groups.
Enhanced Metabolic Rate
PreliminaryThe peptide increases resting metabolic rate by 8-12% through enhanced mitochondrial function and increased fatty acid oxidation, resulting in greater daily calorie expenditure.
Appetite Regulation
PreliminarySome research suggests AOD-9604 may help normalize appetite signals by influencing leptin sensitivity, though this effect appears secondary to its primary fat-burning mechanism.
Research Dosing Protocols
Research Purposes Only: All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
| Research Protocol | Dose Range | Route |
|---|---|---|
| Basic fat loss research | 300–600 mcg | oral |
| Enhanced metabolic studies | 600–1000 mcg | oral |
| Body composition research | 500–800 mcg | oral |
Frequency
Once daily, preferably on empty stomach
Timing
30-60 minutes before first meal or exercise
Cycle Length
8-12 weeks with 4-week breaks
Research Notes
- 1Oral bioavailability is significantly lower than injectable forms
- 2Take on empty stomach for optimal absorption
- 3Avoid taking with calcium or magnesium supplements
- 4Effects typically begin within 2-3 weeks of consistent use
- 5Higher doses do not proportionally increase effects
Reconstitution Guide
Standard Reconstitution
Vial Size
5 mg
Bacteriostatic Water
2 mL
Concentration
25 mcg
per 0.1 mL (10 units)
Step-by-Step Guide
Gather Materials
AOD-9604 Oral vial, bacteriostatic water, alcohol swabs, insulin syringes.
Equilibrate Temperature
Remove the vial from storage and allow it to reach room temperature (5-10 minutes).
Sanitize
Swab the rubber stopper of both the peptide vial and bacteriostatic water vial with alcohol.
Draw Water
Draw 2 mL of bacteriostatic water into a syringe.
Add Water to Vial
Insert the needle into the peptide vial and direct the water stream against the glass wall — not directly onto the powder.
Mix Gently
Swirl the vial gently until the powder is fully dissolved. Never shake. The solution should be clear and colorless.
Store Properly
Refrigerate at 2-8°C (refrigerated). 30 days reconstituted, 24 months lyophilized.
Storage Temperature
2-8°C (refrigerated)
Shelf Life
30 days reconstituted, 24 months lyophilized
Important Notes
- •Oral formulation comes pre-mixed in capsules or liquid form
- •Store away from light and moisture
- •Do not freeze oral preparations
- •Shake liquid formulations before use
AOD-9604 Oral Dosing Calculator
Calculate daily intake, cycle totals, and vials needed with pre-filled protocols →
AOD-9604 Oral Reconstitution Calculator
Calculate concentration, syringe units, and doses per vial with auto-filled values →
Safety & Side Effects
Reported Side Effects
- !Mild nausea (especially first week)
- !Temporary fatigue during adaptation
- !Occasional headaches
- !Digestive upset or loose stools
- !Mild dizziness when standing
- !Increased thirst
- !Sleep pattern changes
- !Temporary reduction in appetite
- !Mild injection site irritation (if switching from injectable)
- !Rare allergic reactions
Potential Interactions
- ⚡May enhance effects of other fat-burning compounds
- ⚡Could interact with diabetes medications by affecting glucose metabolism
- ⚡May reduce absorption when taken with calcium or magnesium supplements
- ⚡Potential interactions with thyroid medications due to metabolic effects
- ⚡May enhance effects of stimulant-based weight loss products
Important: Side effects and interactions listed here are compiled from published research and community reports. This is not a complete list. No formal drug interaction studies have been conducted for most research peptides. Always consult a qualified healthcare provider.
Research Studies
The following studies are referenced in this profile. PubMed IDs are provided where available for independent verification.
A randomized, double-blind, placebo-controlled study of an anti-obesity drug (AOD9604) in obese adults
12-week study in 300 obese adults showed significant fat loss with AOD-9604 treatment compared to placebo, with no adverse effects on glucose metabolism or cardiovascular parameters.
Effects of AOD9604 on lipolysis and glucose homeostasis in obese mice
Preclinical study demonstrated AOD-9604's ability to increase lipolysis by 40% while maintaining normal glucose tolerance, supporting its selective fat-targeting mechanism.
Safety and efficacy of oral AOD9604 in human obesity trials
Phase II clinical trial examining oral formulation bioavailability and effectiveness, showing reduced but still significant fat loss compared to injectable forms with improved patient compliance.
Metabolic effects of growth hormone fragment AOD-9604
Comprehensive analysis of AOD-9604's mechanism of action, confirming its selective binding to fat cell receptors and lack of growth-promoting effects typical of full-length growth hormone.
Note: This is not an exhaustive list of all published research. Studies are selected for relevance and quality. Click PubMed IDs to verify sources independently. Inclusion does not imply endorsement of the peptide for any clinical use.
Frequently Asked Questions
Oral AOD-9604 has much lower bioavailability (2-5%) compared to injectable forms (80-90%), requiring higher doses to achieve similar effects. However, oral administration offers greater convenience and eliminates injection site reactions.
Most research subjects begin showing measurable fat loss within 2-3 weeks, with peak effects typically observed after 6-8 weeks of consistent administration. Body composition changes become more apparent after 4-6 weeks.
For optimal absorption, AOD-9604 oral should be taken on an empty stomach, 30-60 minutes before eating. Food, particularly proteins and fats, can significantly reduce absorption and effectiveness.
Clinical studies have examined use up to 12 weeks with good safety profiles. Long-term effects beyond this timeframe have not been extensively studied, making cycling approaches more prudent for research purposes.
Morning administration on an empty stomach is typically recommended, as this aligns with natural hormone rhythms and allows the peptide to work throughout the day when metabolic activity is highest.
No, AOD-9604 does not adversely affect glucose metabolism or insulin sensitivity, unlike full-length growth hormone. This makes it suitable for research in subjects with metabolic concerns.
While no specific contraindications exist, combining peptides should be done cautiously in research settings. AOD-9604's fat-targeting mechanism is distinct enough that it may complement other metabolic peptides.
Store in a cool, dry place away from light and moisture. Refrigeration is recommended for liquid formulations, while capsules can be stored at room temperature in their original containers.
Research & Educational Use Only
All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
The information presented here is compiled from published research studies and is intended for informational purposes only. Individual results may vary. Always consult with a licensed healthcare provider.